| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Epidemiology of prostate cancer
|
Crawford, E.David
|
|
2003
|
62 |
6S1 |
p. 3-12
10 p.
|
artikel
|
| 2 |
Evolution of therapeutic approaches with luteinizing hormone–releasing hormone agonists in 2003 1 1 Judd W. Moul has been a member of the Speaker's Bureau for AstraZeneca, Bayer, and TAP, and is a study investigator funded by AstraZeneca
|
Moul, Judd W
|
|
2003
|
62 |
6S1 |
p. 20-28
9 p.
|
artikel
|
| 3 |
Exploring the effects of luteinizing hormone–releasing hormone agonist therapy on bone health: implications in the management of prostate cancer
|
Chang, SAM S
|
|
2003
|
62 |
6S1 |
p. 29-35
7 p.
|
artikel
|
| 4 |
Introduction
|
Crawford, E.David
|
|
2003
|
62 |
6S1 |
p. 1-2
2 p.
|
artikel
|
| 5 |
Luteinizing hormone–releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant
|
Marks, LEONARD S
|
|
2003
|
62 |
6S1 |
p. 36-42
7 p.
|
artikel
|
| 6 |
Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks
|
Crawford, E.DAVID
|
|
2003
|
62 |
6S1 |
p. 13-19
7 p.
|
artikel
|
Tijdschrift beschrijving